Methylene Blue

Methylene blue is a synthetic dye and medication, not an herb. FDA-approved methylene blue injection is an intravenous treatment for acquired methemoglobinemia in children and adults and is used under clinical supervision. This page is for research only and does not support self-treatment.

What It Is

Methylene blue is a synthetic chemical with drug and dye uses. Its history does not demonstrate a modern wellness benefit. The FDA indication for the approved injection is acquired methemoglobinemia, a condition in which hemoglobin is impaired in carrying oxygen, rather than general vitality or spiritual wellness. Read the FDA prescribing information

Methylene blue has redox properties, and laboratory and animal studies have investigated possible mitochondrial effects. Those observations generate research questions; they do not show that retail oral drops improve cell energy, meditation, mood, or intuition in people. Review of preclinical and clinical research Evidence review of brain-health claims

The FDA prescribing information reviewed here is for an intravenous prescription product for acquired methemoglobinemia. It does not provide a dropper regimen or a general-wellness indication. A purity claim on an online listing does not by itself establish that oral use is safe or effective. FDA prescribing information

What Human Evidence Shows

Physical well-being can matter to a person's spiritual practice, yet neither fatigue nor a change in meditation experience establishes a treatment effect. Reports of clarity, stable energy, or mood changes are anecdotes, not clinical evidence of benefit.

Researchers have explored methylene blue and related compounds in neurological conditions, but human wellness outcomes remain unestablished. A large randomized phase 3 trial of a related methylthioninium compound did not show treatment benefit for mild-to-moderate Alzheimer's disease. Read the phase 3 trial record

Claims about mitochondrial biogenesis, brain health, cognitive improvement, or anti-aging should be treated as research questions rather than established benefits. The Alzheimer's Drug Discovery Foundation review concludes that there is no evidence that methylene blue benefits human aging or age-related disease. Read the evidence summary

Laboratory antimicrobial activity does not justify self-treating an infection or feeling "run down." Infection symptoms and serious illness need appropriate clinical assessment; methylene blue's approved intravenous indication is acquired methemoglobinemia. FDA prescribing information

Safety and Research Limits

No oral drop count or self-directed dosing regimen is supported here. The FDA-labeled product is an intravenous prescription medicine administered for acquired methemoglobinemia, with dosing and monitoring determined by clinicians for that indication. FDA prescribing information

Online listings, purity descriptions, and droppers do not establish a product's clinical appropriateness or make a dose safe. This guide does not recommend buying, ingesting, or injecting methylene blue for wellness purposes.

Methylene blue can cause serious or fatal serotonin syndrome with serotonergic drugs and opioids. The FDA label advises avoiding concomitant use with SSRIs, SNRIs, MAOIs, and opioids; it also warns that dextromethorphan may increase risk. Anyone considering use should have a clinician or pharmacist review medicines first. FDA boxed warning and interaction information

Starting with a smaller amount does not remove risk. Methylene blue is contraindicated in G6PD deficiency because of severe hemolysis and anemia risk, and it can cause hypersensitivity reactions, confusion, dizziness, and visual disturbances. Urinary discoloration can occur, but it does not demonstrate benefit. FDA contraindications and warnings Safety evidence review

Combining methylene blue with CoQ10, probiotics, or other supplements has not been established as a way to improve cellular health. This guide does not recommend combination protocols.

Wellness impressions are not a substitute for diagnosis, medication review, or urgent care. Methylene blue can cause clinically important adverse effects, and the phase 3 trial of a related methylthioninium compound did not show a treatment benefit for mild-to-moderate Alzheimer's disease. Read the phase 3 trial record